Omrix Biopharmaceuticals, Inc. President And Chief Executive Officer To Ring The NASDAQ Stock Market Opening Bell

NEW YORK, June 2 /PRNewswire-FirstCall/ -- The following is being issued by NASDAQ :

What:

Robert Taub, President and Chief Executive Officer of OMRIX Biopharmaceuticals, Inc. will preside over the opening bell to celebrate its initial public offering on the NASDAQ.

Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio When: Monday, June 5th, 2006 at 9:30 a.m. EDT Contacts: Mike Burshtine Senior Vice President and CFO OMRIX Biopharmaceuticals, Inc. 212-887-6500 mike.burshtine@omrix.com NASDAQ MarketSite: Stephanie Lowenthal; 646.441.5220 Feed Information:

The opening bell is available from 9:20 a.m. to 9:35 a.m. on uplink IA-5 C-band/transponder 14. The downlink frequency is 3980 horizontal; audio: 6.2/6.8. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Stephanie Lowenthal at (646) 441-5220.

Photos:

To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.

About OMRIX Biopharmaceuticals, Inc. [OMRI]:

OMRIX, a commercial-stage Company, develops and markets innovative biosurgical and passive immunotherapy products, utilizing its proprietary protein purification technology and manufacturing know-how. OMRIX commercializes its range of biosurgical hemostats through a partnership with Ethicon, Inc., a Johnson and Johnson company. Also through this partnership, OMRIX is developing highly-innovative surgical products that combine biologics with a surgical device to address unmet medical needs. OMRIX’s business strategy includes proprietary product development for both its biosurgical and immunotherapy product lines and, where appropriate, partnering with companies whose development and/or commercial capabilities complement OMRIX’s own areas of expertise. For more information, please visit: http://www.omrix.com.

NASDAQ

CONTACT: Mike Burshtine, Senior Vice President and CFO of OMRIXBiopharmaceuticals, Inc., +1-212-887-6500, mike.burshtine@omrix.com; orStephanie Lowenthal of NASDAQ MarketSite, +1-646-441-5220

MORE ON THIS TOPIC